Paper · 33256240
The Role of BRAF in Metastatic Colorectal Carcinoma-Past, Present, and Future.
Djanani A and 4 others. Int J Mol Sci, 2020. Cited by 17 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. The Role of BRAF in Metastatic Colorectal Carcinoma-Past, Present, and Future. Papers, record 33256240. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33256240
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Colorectal Neoplasms | Major topic |
| Proto-Oncogene Proteins B-raf | Major topic |
| Animals | |
| Drug Resistance, Neoplasm | |
| Humans | |
| Molecular Targeted Therapy | |
| Neoplasm Metastasis | |
| Signal Transduction |
Source PubMed
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References115
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27,198,569 | PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes. | Mod Pathol | 2016 | https://conductscience.org/library/papers/27198569 | PubMed |
| 2 | 18,316,791 | Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. | J Clin Oncol | 2008 | https://conductscience.org/library/papers/18316791 | PubMed |
| 3 | 32,919,890 | Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer. | Clin Colorectal Cancer | 2020 | https://conductscience.org/library/papers/32919890 | PubMed |
| 4 | 26,742,998 | Cancer statistics, 2016. | CA Cancer J Clin | 2016 | https://conductscience.org/library/papers/26742998 | PubMed |
| 5 | 25,139,339 | Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. | Clin Cancer Res | 2014 | https://conductscience.org/library/papers/25139339 | PubMed |
| 6 | 21,646,616 | Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer. | J Clin Oncol | 2011 | https://conductscience.org/library/papers/21646616 | PubMed |
| 7 | 8,861,899 | Lessons from hereditary colorectal cancer. | Cell | 1996 | https://conductscience.org/library/papers/8861899 | PubMed |
| 8 | 19,603,024 | Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. | Br J Cancer | 2009 | https://conductscience.org/library/papers/19603024 | PubMed |
| 9 | 32,249,628 | The discovery and development of binimetinib for the treatment of melanoma. | Expert Opin Drug Discov | 2020 | https://conductscience.org/library/papers/32249628 | PubMed |
| 10 | 16,649,144 | Back to the roots: the remarkable RAF oncogene story. | Cell Mol Life Sci | 2006 | https://conductscience.org/library/papers/16649144 | PubMed |
1 to 10 of 115
See all 115 referencesCited by13
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 17 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,588,662 | Factors Associated with the Timing of Liver Metastasis After Colorectal Cancer Surgery: A Retrospective Multicenter Study. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42588662 | PubMed |
| 42,185,244 | Cost-effectiveness analysis of encorafenib in untreated BRAF V600E-mutant metastatic colorectal cancer in China. | Pharmacogenomics J | 2026 | https://conductscience.org/library/papers/42185244 | PubMed |
| 41,439,081 | Molecular Profiling of KRAS, NRAS, and BRAF in Colorectal Cancer: Insights From a Libyan Cohort. | Cureus | 2025 | https://conductscience.org/library/papers/41439081 | PubMed |
| 40,619,745 | Adagrasib in the treatment of colorectal cancer. | Future Oncol | 2025 | https://conductscience.org/library/papers/40619745 | PubMed |
| 40,234,937 | LINC02167 stabilizes KSR1 mRNA in an m5C-dependent manner to regulate the ERK/MAPK signaling pathway and promotes colorectal cancer metastasis. | J Exp Clin Cancer Res | 2025 | https://conductscience.org/library/papers/40234937 | PubMed |
| 40,083,375 | Precision medicine in colorectal cancer: genomics profiling and targeted treatment. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/40083375 | PubMed |
| 39,591,358 | Expression of Mutated BRAFV595E Kinase in Canine Carcinomas-An Immunohistochemical Study. | Vet Sci | 2024 | https://conductscience.org/library/papers/39591358 | PubMed |
| 38,940,668 | Progress in clinical diagnosis and treatment of colorectal cancer with rare genetic variants. | Cancer Biol Med | 2024 | https://conductscience.org/library/papers/38940668 | PubMed |
| 38,136,364 | In Vitro Organoid-Based Assays Reveal SMAD4 Tumor-Suppressive Mechanisms for Serrated Colorectal Cancer Invasion. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/38136364 | PubMed |
| 36,811,382 | A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF V600E-Mutant KRAS Wild-Type Metastatic Colorectal Cancer. | Oncologist | 2023 | https://conductscience.org/library/papers/36811382 | PubMed |
1 to 10 of 13
See all 13 cited byGenes26
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AKT1 | 207 | PubTator's text mining | https://conductscience.org/library/genes/207 | NCBI Gene |
| APC | 324 | PubTator's text mining | https://conductscience.org/library/genes/324 | NCBI Gene |
| ARAF | 369 | PubTator's text mining | https://conductscience.org/library/genes/369 | NCBI Gene |
| BRAF | 673 | PubTator's text mining | https://conductscience.org/library/genes/673 | NCBI Gene |
| CD274 | 29,126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| CTLA4 | 1,493 | PubTator's text mining | https://conductscience.org/library/genes/1493 | NCBI Gene |
| CTNNB1 | 1,499 | PubTator's text mining | https://conductscience.org/library/genes/1499 | NCBI Gene |
| EGF | 1,950 | PubTator's text mining | https://conductscience.org/library/genes/1950 | NCBI Gene |
| EGFR | 1,956 | PubTator's text mining | https://conductscience.org/library/genes/1956 | NCBI Gene |
| ERBB2 | 2,064 | PubTator's text mining | https://conductscience.org/library/genes/2064 | NCBI Gene |
1 to 10 of 26
See all 26 genesDrugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33256240
GET https://conductscience.org/api/papers/v1/33256240/references?page=2